Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

EPICS-III shows saroglitazar potential for select PBC patients
08 Jun 2026
bởiAudrey Abella
In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).
EPICS-III shows saroglitazar potential for select PBC patients
08 Jun 2026
Dupilumab improves AD symptoms in adult Asians
06 Jun 2026
bởiStephen Padilla
Treatment with dupilumab results in significant improvements in the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adult Asian patients without any serious adverse effects, a Singapore study has shown.







